Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Variagenics presses on with cancer diagnostics:

This article was originally published in Clinica

Executive Summary

Variagenics has moved a step closer to its aim of developing molecular diagnostic tests predictive of the response of solid tumours to chemotherapy. The Cambridge, Massachusetts firm has begun its first clinical study to identify genetic markers for chemotherapeutic toxicity. The retrospective study will involve the genetic analysis of over 100 patients who have experienced severe side effects following 5-fluorouracil chemotherapy for colorectal cancer.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts